Introduction
============

Coagulation factor V is a coagulation protein that is synthesized by the liver and possibly by megakaryocytes. Factor V is present in the blood plasma as a single-chain polypeptide (80%) and in platelet α-granules (20%). Factor V participates in procoagulantion because it is a cofactor of the prothrombinase complex. Factor V also plays an important role in the anticoagulant pathway because it plays a pivotal role in haemostasis: its inactivated form participates in the inactivation of factor VIII via activated protein C (APC). Thus, factor V plays an essential role in both procoagulant and anticoagulant pathways. Factor V functional disorders can cause haemorrhagic or thrombotic events. Acquired factor V deficiency (AFVD) is a rare haemostatic disorder that is generally because of the development of antibodies against factor V. AFVD was first reported in 1955 \[[@R1],[@R2]\], and there are approximately 200 case reports or case series describing this disorder in the current literature. The majority of cases of AFVD have occurred in the presence of associated risk factors that include bovine thrombin exposure during surgical procedures, antibiotic administration (especially antibiotics of the lactam group), cancers, and autoimmune disorders. The clinical manifestations of AFVD are variable and range from asymptomatic laboratory anomalies to fatal haemorrhagic or thromboembolic events. Here, we report a Chinese case of AFVD that presented with haematuria followed by multiple haemorrhages that resulted from an extremely low level of factor V inhibitor and was potentially secondary to a urinary tract infection.

Case report
===========

Our patient was a 64-year-old man who was admitted to our hospital with a 15-day history of haematuria and a 6-day history of nose and tonsil bleeding.

The patient was previously evaluated in another hospital, and levofloxacin was prescribed with a diagnosis of cystitis. The coagulation profile revealed both a prolonged prothrombin time (PT) of 113.80 s (11--14.5 s) and an activated partial thromboplastin time (APTT) of more than 180 s (28--45 s). Haemostatic drugs were prescribed for his bleeding. However, these drugs did not correct his PT or APTT, and he subsequently developed nose and tonsil bleeding. His past medical history included prostatic hyperplasia for 10 years and a surgery after a car accident in 2011. However, he had no history of significant coagulation disorders with prior surgical procedures or other family bleeding history. He had no documented history of medicines. Upon physical examination, slight tenderness was present on epigastric palpation and kidney region percussion. Upon laboratory examination, his haemoglobin level was 105 g/l (115--150 g/l), his red blood cell count was 3.28 × 10^9^/l (3.8--5.1 × 10^9^/l), his white blood cell count was 7.9 × 10^9^/l (3.5--9.5 × 10^9^/l), his platelet count was 162 × 10^9^/l (125--350 × 10^9^/l), and his fibrinogen was 3.98 g/l (2--4 g/l). The blood chemistry revealed no liver dysfunction (Table [1](#T1){ref-type="table"}). The coagulation profile revealed both a prolonged PT of 51.70 s (11--14.5 s) and an APTT of more than 180 s (28--45 s; Table [2](#T2){ref-type="table"}). His factor V activity was markedly reduced (2% of normal; Table [3](#T3){ref-type="table"}). The levels of factors VII/VIII and factor IX were within the reference ranges. His blood chemistry was unremarkable. The overall results indicated the presence of antibodies against factor V and suggested a diagnosis of AFVD. A standard Bethesda assay confirmed the presence of factor V inhibitor with a low level of 1.9 BU. The patient received an infusion of fresh frozen plasma (FFP) with a partial correction of his coagulation parameters (Table [2](#T2){ref-type="table"}). Subsequently, the factor V inhibitor was undetectable. However, the FFP exhibited no obvious effect on restoring the plasma factor V activity (Table [3](#T3){ref-type="table"}). The patient was discharged because his bleeding stopped.

On 24 April 2015, 45 days after his initial visit, the patient was readmitted to our hospital with a 3-day history of gingival haemorrhage and haematoma of the right lower limb (Fig. [1](#F1){ref-type="fig"}). On examination, with the exception of the gingival haemorrhage and skin bruising on his right lower limb, the patient exhibited no other bleeding or bruising, nor was any area abnormal. A complete blood count revealed normal white blood cell and platelet levels of 8.48 × 10^9^ and 144 × 10^9^/l, respectively, but a reduced haemoglobin value of 67 g/l, which indicated anaemia because of blood loss. On investigation of his coagulation parameters, a prolonged PT of 63.6 s, an APTT of 188.7 s, and a marked reduction in factor V activity (3% of normal) were noted (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). We immediately administered the patient a transfusion of 2 units of red blood cells and 250 ml FFP followed by another 7 days of FFP transfusions at the dose of 200 ml/day with concurrent monitoring of PT/APTT and factor V activities. The FFP transfusion ultimately resulted in a correction of the PT/APTT values to normal limits. The factor V activity was partially corrected from 3 to 22%. A further evaluation for congenital factor V deficiency did not reveal a factor V Leiden genotype, and the evaluations of factor II, protein C, protein S, SERPINC 1, cytochrome P450 4F2 (CYP4F2), cytochrome P450 4V2 (CYP4V2), kallikrein B1 (KLKB1), and Janus kinase 2 (JAK2) mutation were normal, but a c.1538G\>A (1628G\>A, Arg485Lys) mutation was detected (Fig. [2](#F2){ref-type="fig"}). However, screening assays of his relatives revealed that his two daughters and his brother and sister also carried this mutation but never exhibited coagulation disorders. Indeed, the c.1538G\>A (1628G\>A, Arg485Lys) mutation has been proved to be a polymorphism in people that does not influence the factor V procoagulant activity. After congenital factor V deficiency was ruled out, the patient was started on methylprednisolone (60 mg/day). Five days after the initiation of the steroid treatment, the bleeding symptoms were completely resolved, the bruising on the right lower limb disappeared gradually, serial measurements of the PT/APTT levels remained stable within the reference ranges, and the factor V activity increased to normal (77%, Table [3](#T3){ref-type="table"}). Further follow-up showed his coagulation parameters (PT/APTT) and factor V activity were normal and no factor V inhibitors were detected (Table [4](#T4){ref-type="table"}).
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Discussion and literature review
================================

AFVD is a rare haemostatic disorder; the clinical manifestations of which are variable and range from asymptomatic haematological laboratory abnormalities to life-threatening haemorrhaging or thromboembolic events. Acquired factor V inhibitors are rare causes of clinical bleeding with severities that range from mild to life threatening. Notably, multiple bleeding sites are infrequently and simultaneously (32%) involved \[[@R3]\]. Mucous membranes (i.e. the gastrointestinal, genitourinary, and airway tracts) are most frequently involved in the bleeding. The mortality rate of patients with haemorrhages can reach 21% \[[@R4]\]. Thrombotic events are rare. Notably, only six patients on factor V inhibitors have presented with thrombotic manifestations that include limb gangrene \[[@R5]\], multiple cerebral infarctions \[[@R6]\], deep vein thromboli \[[@R7]--[@R9]\], and upper extremity thrombi \[[@R10]\].

In the present case, the patient initially presented with haematuria and subsequently developed multiple haemorrhages that included nose bleeding, tonsil bleeding, gingival bleeding, and haematoma. Because multiple haemorrhages are frequently involved in AFVD, we assume that AFVD should be considered for patients who present with bleeding, particularly those who present with multiple haemorrhages.

AFVD is generally because of the development of antibodies against factor V. Regarding the conditions associated with the development of factor V inhibitors, a review of 148 cases of AFVD between 1955 and 2010 in the literature revealed that the majority of these cases were associated with exposure to bovine thrombin during surgical procedures, antibiotics (cephalosporins, aminoglycosides, and penicillins), infections, malignancies, and autoimmune diseases \[[@R3]\]. However, the author noted that it was difficult to prove causation or association in many of these cases.

A PubMed and CNKI search from 2010 to 2016 and a subsequent search from 1955 to 2016 were performed with the limits of only the English and Chinese languages (abstracts and reports in other language were also included as long as they had sufficient interpretable information to fulfil the criteria) using the following terms: 'acquired factor V deficiency', 'acquired factor V inhibitors', 'acquired inhibitors and coagulation factors', 'antifactor V antibodies', 'factor V autoantibodies', 'autoimmune factor V inhibitors', 'spontaneous inhibitors', and 'factor V'.

According to the procedure illustrated in Fig. [3](#F3){ref-type="fig"}, we obtained 34 case reports or series (45 cases) from PubMed and three case reports or series seven cases) from CNKI (Table [5](#T5){ref-type="table"}). We reviewed this total of 52 cases of AFVD since 2010 for the underlying conditions of AFVD. Bovine thrombin, which contains only human-derived compounds, was minimally found in the cases; bovine thrombin exposure was only present in four of the 52 cases. In the nonbovine-associated factor V deficiency cases, surgical procedures were present in nine of the 48 nonbovine-associated cases (19%), the use of antibiotics accounted for 19% (9/48), and autoimmune diseases and drugs other than antibiotics both accounted for 9% (4/48). Tumours and other diseases each accounted for 8% (4/48), and infections and transplantations accounted for 13% (6/48) and 4% (2/48), respectively. Interestingly, there were also 13 idiopathic cases (27%, Table [6](#T6){ref-type="table"}). We systematically reviewed 200 cases of AFVD from 1955 to 2016 for the underlying conditions of AFVD. Bovine thrombin exposure was present in 74 of the 200 cases. In the nonbovine-associated factor V inhibitor cases, the use of antibiotics was present in 42 of the 126 cases of nonbovine thrombin exposure (33%). Surgical procedures accounted for 26% (33/126), tumours accounted for 17% (21/126), autoimmune diseases accounted for 11% (14/126), infections accounted for 17% (22/126), transplantations accounted for 5% (6/126), and drugs other than antibiotics accounted for 4% (5/126). There were also 29 idiopathic cases (23%, Table [7](#T7){ref-type="table"}).
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In the present case, the patient had histories of prostatic hyperplasia for 10 years, a surgery, a recent urinary tract infection and the use of antibiotics. The patient had no familial or personal history of coagulopathy. His initial coagulation parameters (PT/APTT) and those during the surgery were normal. Moreover, prior to the initiation of antibiotics, he developed haematuria and multiple haemorrhages. Because hepatitis virus infections and liver dysfunction have been associated with factor V inhibitors \[[@R3]\], the patient\'s liver function was evaluated to rule out liver disease as a potential cause. However, this patient exhibited no liver dysfunction, liver failure, or hepatitis virus infection as indicate by these laboratory findings (Table [1](#T1){ref-type="table"}). Therefore, we assumed the development of the factor V inhibition was associated with a urinary tract infection. Our case is not the only case that has been associated with urinary tract infection. Two other cases involving antibiotics accompanied with urinary tract infections related to conditions of AFVD have been reported \[[@R11],[@R12]\], including one case with a urinary tract infection and the use of ciprofloxacin and an additional case with a urinary tract infection and the use of cephradine. The latter case highlighted that the relationship between the formation of factor V inhibitors and cephradine treatment is probable. Therefore, our case is the first reported AFVD case with a urinary tract infection as the only associated condition. The underlying mechanism might be immunologic dissonance triggered by a urinary tract infection. However, we would like to highlight that it is difficult to be certain that the urinary tract infection played a causative role in this patient in terms of either the development of the inhibitors or the bleeding.

The identification of factor V inhibitors typically occurs in association with prolonged PT and APTT and/or an isolated factor V deficiency in patients with otherwise negative personal and familial haemorrhagic histories. The inhibitor was confirmed and titrated using the traditional Bethesda method. The median peak inhibitor titre was 19 BU (0.5--1500 BU), whereas the median factor V activity level was 1% (1--20%). The inhibitor titre does not correlate with the factor V deficiency level nor with the bleeding risk (the median inhibitor titres in both bleeders and nonbleeders are 19 BU) \[[@R3]\].

In the present case, the factor V inhibitor was initially titrated at 1.9 BU and was subsequently undetectable after the FFP transfusion, which indicates that this was a rare case with an extremely low factor V inhibitor level. The infusion of factor V in FFP was presumed to neutralize some of the inhibitory activity.

Factor V deficiency can be inherited or acquired
------------------------------------------------

Congenital factor V deficiency is an autosomal recessive disease with a prevalence of approximately 1/1 000 000. The mechanism underlying this disorder may involve genetic changes that affect the protein C anticoagulant system, such as the APC caused by a factor V Leiden mutation, deficiencies of protein C, protein S or antithrombin, and increased levels of factor VIII or prothrombin \[[@R13]\]. In terms of treating congenital factor V deficiency, FFP transfusion can easily correct this disorder.

In the present case, evaluations for congenital factor V deficiency did not reveal any possible underlying reason with the exception of the c.1538G\>A (1628G\>A, Arg485Lys) mutation. The 1628G\>A mutation at exon 10 of the factor V gene was first described by Gandrille *et al.*\[[@R14]\]. A G\>A transition occurred at nucleotide 1628 in the codon AGA of Arg 485, which was replaced by an AAA codon, which predicted a Lys residue. According to Gandrille, this Lys substitution that occurred at Arg 485 did not influence the APC resistance test nor the factor V procoagulant activity; thus, this substitution is a polymorphism.

Regarding AFVD treatment, it includes bleeding control and the elimination of the factor V inhibitor. FFP, platelet transfusions, and prothrombin complex concentrates have been used in bleeding patients, but the effects of these treatments have mostly been dismal because of the low concentration of factor V. Platelet concentrates can protect factor V from inhibitors thus produce a satisfactory effect in terms of bleeding control. Recombinant-activated factor VII acts as a bypassing agent and has also been successfully used in factor V deficiency cases with severe haemorrhaging. The other principle for managing patients with factor V inhibitors has been the eradication of these inhibitors, and the gold standard has been immunosuppression (i.e. corticosteroids, cyclophosphamide, and rituximab). Corticosteroids can eradicate factor V inhibitors to reduce subsequent bleeding risk because of their immunosuppressive effects. Specifically, immunosuppressive regimens with corticosteroids alone or in association with cyclophosphamide or other immunosuppressants were successfully used to suppress autoantibody production in 76 of 126 cases (60%), and remissions were achieved in 37 of these cases (29%). High intravenous doses of immunoglobulin can rapidly increase factor V activity by reducing factor V inhibitors. Extracorporeal methods, such as plasmapheresis and immunoadsorption, can also reduce factor V inhibitors and thus effectively control bleeding (Table [8](#T8){ref-type="table"}).

In the present case, the PT/APTT decreased following each FFP transfusion but subsequently increased over the following days, which suggests the reequilibration of the inhibitor from the extravascular fluid and the continued production of the inhibitor. After a 5-day course of high-dose corticosteroids, the PT/APTT and factor V activity were both corrected to normal. We assumed that immunosuppressive regimens of corticosteroids can eliminate factor V inhibitors and thus effectively increase the factor V activity and control bleeding.

Conclusion
==========

This is the first reported case of AFVD that is possibly associated only with a urinary tract infection. The clinical and laboratory features and treatment of this disease were discussed. Additionally, we systematically reviewed 200 cases of AFVD from 1955 to 2016 for the conditions underlying AFVD.

Acquired inhibitors of factor V are rare causes of clinical bleeding, and multiple haemorrhages are not rare. Therefore, we assume that AFVD should be kept in mind for patients who present with bleeding, especially those who present with multiple haemorrhages, and immediate treatment should be administered because the condition may cause life-threatening complications.
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###### 

Laboratory findings

  Blood chemistry                                          
  ----------------- -------------------------- ----------- --------------------------
  ALT               17 (9--50 IU/l)            K           3.78 (3.50--5.30 mmol/l)
  AST               15 (15--40 IU/l)           Cl          103 (99--110 mmol/l)
  GGT               31 (10--60 IU/l)                       
  AKP               90 (45--125 IU/l)          Serology    
  LDH               270 (120--230 IU/l)        HBsAg       --
  TP                73.2 (6.0--85.0 g/l)       HBsAb       --
  ALB               45.2 (40.0--55.0 g/l)      HBeAg       --
  TBIL              5.3 (5.0--21.0 μmol/l)     HBeAb       --
  DBIL              2.1 (0.0--6.0 μmol/l)      HBcAb-IgG   --
  IBIL              3.2 (2.0--15.0 μmol/l)     HCV Ab      --
  BUN               5.68 (2.30--7.80 mmol/l)   HCV Ag      --
  Cr                65 (262--115 μmol/l)       PreS1-Ag    --
  Na                142 (137--147 mmol/l)      TP-Ab       --

AKP, alkaline phosphatase; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate transaminase; BUN, blood urea nitrogen; CYP4F2, cytochrome P450 4F2; CYP4V2, cytochrome P450 4V2; DBIL, direct bilirubin; GGT, γ-glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HBsAb, antibody to hepatitis B surface antigen; HBeAg, hepatitis B e-antigen; HBeAb, antibody to hepatitis B e-antigen; HBcAb, antibody to hepatitis B core antigen; HCV Ab, antibody to hepatitis C virus; HCV Ag, hepatitis C antigen; IBIL, indirect bilirubin; JAK2, Janus kinase 2; KLKB1, kallikrein B1; LDH, lactic dehydrogenase; PreS1-Ag, PreS1 antigen; SERPINC 1, serpin C1; TBIL, total bilirubin; TP, total protein; TP-Ab, treponema pallidum antibody; --, negative.

###### 

Prothrombin time and activated partial thromboplastin time results after the first and second admissions
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###### 

Factor V activity results after the first and second admissions
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###### 

Follow-up results

  ----------------- ------------ -------------- ------------------ ------------------- ------------------- ----------------- ------------------ -----------------
  Date              2 May 2015   30 July 2015   3 September 2015   10 September 2015   20 September 2015   27 October 2015   11 November 2015   21 January 2016
  PT                             11.8 s                                                13.4 s              12.9 s            14.6 s             20.1 s
  APTT                           23.5 s                                                37.6 s              28.5 s            31.1 s             52.1 s
  FV activity (%)   127          121            73                 143                                                                          
  FV inhibitor      0 BU/ml                                                                                                                     
  ----------------- ------------ -------------- ------------------ ------------------- ------------------- ----------------- ------------------ -----------------

APTT, activated partial thromboplastin time; BU, Bethesda units; FV, factor V; PT, prothrombin time.

###### 

Acquired factor V deficiency cases: data in the literature

  No.   Year   Sex   Age      Symptoms at diagnosis                                                      Associated drug/condition                                                                       Inhibitor (BU/ml)   FV activity    Treatment                               Outcome
  ----- ------ ----- -------- -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------- -------------- --------------------------------------- ------------------------
  1     2010   M     71       Gross haematuria + gastrointestinal bleeding + left groin haematoma        CPS, UTI                                                                                        6.6                 6.2%           Steroids                                Death
  2     2010   F     88       No                                                                         CPS                                                                                             4                   6%             RBC + FFP + rFVIIa + PLT + IVIg + RTX   Inhibitor persistence
  3     2010   M     74       Epistaxis                                                                  Laparoscopic low anterior resection of rectal cancer[^a^](#TF5-1){ref-type="table-fn"}          --                  --             Plasmapheresis + rFVIIa + PLT           Inhibitor persistence
  4     2010   M     3        No                                                                         CTS[^b^](#TF5-2){ref-type="table-fn"}                                                           0--1.0              \<6%           IVIg + steroids                         Remission
  5     2010   F     38       Excessive bleeding                                                         Burn surgery[^b^](#TF5-2){ref-type="table-fn"}                                                  9                   --             FFP                                     Partially corrected
  6     2010   F     84       No                                                                         Valve replacement[^b^](#TF5-2){ref-type="table-fn"} + pyelonephritis + antibiotics + warfarin   8                   4%             Steroids                                Remission
  7     2011   F     28       Gastrointestinal bleeding                                                  LT[^a^](#TF5-1){ref-type="table-fn"}                                                            10                  \<1%           FFP + PCC + steroids + IVIg             Inhibitor persistence
  8     2011   F     59       Melena                                                                     Ovarian tumour                                                                                  10--18              2.1%           Plasmapheresis                          Relapse
  9            M     67       No                                                                         Antibiotics + UC                                                                                3                   1.6%           No                                      Spontaneous resolution
  10           M     64       Haematuria + bleeding in soft tissues                                      None                                                                                            3                   4%             Cyclosporin A                           Remission
  11    2011   M     88       Microscopic haematuria                                                     Hashimoto\'s thyroiditis                                                                        4.3                 1%             Steroids                                Remission
  12    2011   M     79       POB                                                                        Right hip arthroplasty[^a^](#TF5-1){ref-type="table-fn"}                                        3                   15%            PLT + CTX + steroids                    Remission
  13    2011   F     80       Gastrointestinal bleeding                                                  None                                                                                            17                  \<3%           Steroids                                Inhibitor persistence
  14    2012   M     85       Chest wall haematoma                                                       Antibiotics                                                                                     \>50                0              Steroids + PLT + IVIg + CTX             Remission
  15    2012   M     --       Bleeding                                                                   Amiodarone                                                                                      32.2                3.38%          Steroids + CTX                          Remission
  16    2012   M     70       Intracerebral haemorrhage                                                  MPA                                                                                             --                  0%             FFP + plasmapheresis                    Death
  17    2012   F     73       Purpura                                                                    None                                                                                            1.4                 2%             Steroids                                Inhibitor persistence
  18    2012   F     79       Melena + bruises                                                           None                                                                                            2.0                 \<1%           FFP + PLT                               Lost follow-up
  19    2012   M     51       Epistaxis + Haematuria                                                     None                                                                                            16                  1.1%           FFP + steroids + CTX                    Remission
  20           F     61       Gum bleeds                                                                 None                                                                                            0                   0.6%           Steroids                                Remission
  21           M     71       Melena + bruises                                                           None                                                                                            3                   0.5%           FFP + PCC + steroids + CTX              Death
  22    2012   F     72       Haematoma in the oral cavity                                               None                                                                                            --                  \<2%           CTX + RTX                               Inhibitor persistence
  23           M     51       Haematuria + gum bleeds + epistaxis+ haematomas in upper and lower limbs   None                                                                                            17                  \<3%           PLT + steroids + CTX + AZT + RTX        Remission
  24    2012   M     8 days   Umbilical bleeding + haematuria                                            Pneumonia + cefaclor                                                                            --                  3.6%           RBC + FFP                               Remission
  25    2012   F     82       DVT                                                                        Aspirin, clopidogrel, PCI for UA[^a^](#TF5-1){ref-type="table-fn"}                              4                   2%             Steroids                                Remission
  26    2013   M     85       Skin bleeding                                                              Warfarin                                                                                        11                  \<2%           Steroids                                Remission
  27    2013   M     62       Cerebral haemorrhage + purpura                                             MN                                                                                              4.4                 2.5%           Steroids                                Remission
  28    2013   M     82       Epistaxis + Haematuria + Melena                                            SCC of oesophagus                                                                               12                  2%             Steroids                                Death
  29    2014   M     90       Generalized ecchymoses                                                     DEM                                                                                             4                   \<3%           Steroids                                Inhibitor persistence
  30    2014   M     64       Haematuria                                                                 MCL                                                                                             80                  \<0.01 IU/ml   Steroids                                Remission
  31    2014   F     64       No                                                                         None                                                                                            --                  1%             FFP + steroids + IVIg                   Inhibitor persistence
  32    2014   M     80       No                                                                         Antibiotics                                                                                     --                  --             --                                      Remission
  33    2014   M     --       No                                                                         Chronic thyroiditis                                                                             4.3                 2.3 IU/dl      --                                      --
  34           M     --       No                                                                         Progressive supranuclear palsy                                                                  5.4                 11.5 IU/dl     --                                      --
  35           M     --       No                                                                         IPMNs of the pancreas                                                                           11.8                \<1.0 IU/dl    --                                      --
  36           M     --       No                                                                         AF                                                                                              1.7                 \<1.0 IU/dl    --                                      --
  37           F     --       No                                                                         None                                                                                            8.7                 1.7 IU/dl      --                                      --
  38           M     --       Severe bleeding                                                            AP, asthma                                                                                      118                 8.0 IU/dl      --                                      --
  39           F     --       Severe bleeding                                                            Valve replacement[^a^](#TF5-1){ref-type="table-fn"}                                             16                  \<1.0 IU/dl    --                                      --
  40           M     --       Severe bleeding                                                            CRF                                                                                             64                  \<1.0 IU/dl    --                                      --
  41           M     --       Severe bleeding                                                            None                                                                                            9.9                 \<1.0 IU/dl    --                                      --
  42           M     --       Severe bleeding                                                            None                                                                                            8.2                 \<1.0 IU/dl    --                                      --
  43    2014   F     67       Epistaxis + urethral bleeding + mucosal mouth bleeding                     Aortic aneurysm surgery                                                                         7.76                5%             FFP + steroids                          Remission
  44    2014   M     61       Haemoptysis                                                                Lung surgery for empyema[^a^](#TF5-1){ref-type="table-fn"}                                      83                  \<3%           Steroids + RTX                          Remission
  45    2014   M     54       Gastrointestinal bleeding                                                  LT[^a^](#TF5-1){ref-type="table-fn"}                                                            9                   0.6%           FFP + PLT + PCC + rFVIIa + IVIg         Remission
  46    2014   M     67       Intra-abdominal bleeding                                                   Hepatectomy for HCC[^b^](#TF5-2){ref-type="table-fn"}                                           --                  \<50%          Steroids                                Remission
  47    2014   M     82       No                                                                         Valve replacement[^a^](#TF5-1){ref-type="table-fn"}                                             16                  \<1%           No                                      Death
  48    2015   M     53       Haematuria                                                                 Surgery                                                                                         6                   1%             RTX + IVIg + plasmapheresis             Remission
  49    2015   M     84       No                                                                         Surgery for a ruptured intracerebral haemangioma[^a^](#TF5-1){ref-type="table-fn"}              212                 \<5%           PLT + PCC                               Death
  50    2015   M     59       No                                                                         CAZ                                                                                             10                  2%             Steroids                                Remission
  51    2016   F     64       Upper-extremity thrombus                                                   PTZ, CFX                                                                                        5                   2%,            Steroids                                Remission
  52           F     75       Minor ecchymosis                                                           PTZ, HCV                                                                                        21.76               \<1%           Steroids                                Remission

AF, atrial fibrillation; AFVD, acquired factor V deficiency; AP, aspiration pneumonia; AZT, azathioprine; CAZ, ceftazidime; CFX, ciprofloxacin; CPS, cephalosporin; CRF, Chronic renal failure; CTS, cardiothoracic surgery; CTX, cyclophosphamide; DEM, dabigatran etexilate methanesulfonate; DVT, deep vein thrombosis; F, female; FFP, fresh frozen plasma; FV, factor V; HCC, hepatocellular carcinoma; IPMNs, intraductal papillary-mucinous neoplasms; IVIg, intravenous immunoglobulin; LT, liver transplantation; M, male; MCL, mantle cell lymphoma; MN, Membranous nephropathy; MPA, microscopic polyangiitis; ND, no data; PCC, prothrombin complex concentrates; PCI, percutaneous coronary intervention; PLT, platelet; POB, postoperative bleeding; PTZ, piperacillin--tazobactam; RBC, red blood cell; rFVIIa, recombinant-activated factor VII; RTX, rituximab; SCC, squamous cell carcinoma; UA, unstable angina; UC, ulcerative colitis; UTI, urinary tract infection.

Not available.

^a^No bovine thrombin exposure.

^b^Bovine thrombin exposure.

###### 

Acquired factor V deficiency cases from 2010 to 2016

  Conditions associated with factor V inhibitors   
  ------------------------------------------------ -------------------------------------
  Bovine thrombin                                  *n* = 4
  Not bovine thrombin                              *n* = 48
  Antibiotics                                      *n* = 9, 19%
  Surgery                                          *n* = 9, 19%
  Tumour                                           *n* = 4, 8%
  Autoimmune disease                               *n* = 4, 8%
  Infection                                        *n* = 6, 13%
  Transplantation                                  *n* = 2, 4%
  Other drugs                                      *n* = 5, 10%
  Other diseases                                   *n* = 4, 8%
  Idiopathic                                       *n* = 13, 27%
                                                   (Proportion of not bovine thrombin)

###### 

Acquired factor V deficiency cases from 1955 to 2016

  Conditions associated with factor V inhibitors   
  ------------------------------------------------ -------------------------------------
  Bovine thrombin                                  *n*  =  74
  Not bovine thrombin                              *n* = 126
  Antibiotics                                      *n* = 42, 33%
  Surgery                                          *n* = 33, 26%
  Tumour                                           *n* = 21, 17%
  Autoimmune disease                               *n* = 14, 11%
  Infection                                        *n* = 21, 17%
  Transplantation                                  *n* = 6, 5%
  Other drugs                                      *n* = 5, 4%
  Idiopathic                                       *n* = 29, 23%
                                                   (Proportion of not bovine thrombin)

###### 

Treatments for acquired factor V deficiency

  --------------------------------------
  Bleeding control
   Fresh frozen plasma
   Platelet transfusion
   Prothrombin complex concentrates
   Recombinant-activated factor VII
  Eradication of the autoantibody
   Corticosteroids
   Cyclophosphamide
   Rituximab
   Intravenous immunoglobulin
   Plasmapheresis and immunoadsorption
  --------------------------------------
